Women’s health in the United States and across the world continues to worsen, with a widespread lack of access to healthcare and low awareness levels contributing to disparities in outcomes between men and women. Driving prevailing health inequity is a stark gap in medical research, which has been historically performed primarily on male subjects. Women have been excluded from clinical trials throughout history, limiting our understanding of female-specific health conditions and their overall health.
From cardiovascular risk factors to breast cancer and fertility, women’s health encompasses a wide range of complex issues that require specialized attention and research. Despite making up half of the global population, women are largely under-studied and underrepresented in medicine, which extends to the clinical setting. The statistics are telling: Women die at higher rates than men from heart attacks and strokes; they comprise 80 percent of all new cases of autoimmune diseases; and they are three times more likely to experience mental health disorders. The list goes on.
The longevity industry is currently undergoing a revolution. As the result of investment from companies like Google and Amazon and some of the world’s top billionaires, there has been a surge in scientific breakthroughs and technological advancements in the field of aging research. An exciting wave of development is happening in research labs across the globe, with a growing number of longevity science companies, technology centers, and forthcoming human trials.
A growing body of research demonstrates significant discoveries and advancements in knowledge into potential biomedical strategies for reversing the aging process. Today, researchers continue to study animal and human abilities to regenerate cells, aiming to diminish cognitive decline, immune system weakening, and other adverse effects of the biological aging process. Meanwhile, healthcare and biotech companies race to “find the key” to reversing the aging process, bringing the market valuation of anti-aging medicine to a projected $610 billion by 2025 from current estimates of $110 billion. Investors are pouring millions into start-up companies that focus on anti-aging and regenerative medical research, in hopes of being the first organization to make a breakthrough – bringing a successful solution to aging to the public.